LA BioMed Study Seeks to Improve Diabetic Eye Health

Researchers find Divergent Views on Barriers to Diabetic Retinopathy Screening

LOS ANGELES – (Oct. 10, 2016) – While diabetes is the most common cause of blindness in the working-age population in the U.S., only about 55% of lower income adults living with the disease undergo the retinal screening needed to detect and help prevent blindness.

LA County Supervisors Approve Funding for LA BioMed to Help Stimulate Region’s Biosciences Industry

Funding to Help Create Incubator on Institute’s Campus to Help New Businesses Thrive

LOS ANGELES – (Oct. 4, 2016) – The Los Angeles County Board of Supervisors unanimously approved $3 million in funding today to help pay for the creation of a biosciences incubator on LA BioMed’s campus that will provide technical support and business services to help researchers bring promising new discoveries to market so the public can benefit from them.

California Life Sciences Association Partners with LA BioMed and Lab Launch to Grow World-Class Life Sciences Innovation Hub in Los Angeles; Opens Los Angeles Office

Alliances to Strengthen Los Angeles County’s Life Sciences Community

California Life Sciences Association (CLSA), the nation’s largest statewide public policy and business leadership organization representing California’s leading life sciences innovators, today announced new strategic partnerships with LA BioMed and Lab Launch, and the unveiling of its Los Angeles satellite office, to regularly engage and bolster Los Angeles County’s life sciences community.

New Chief Scientific Officer Joins LA BioMed

Dr. Joaquín Madrenas Brings Decades of Research Experience to the Institute

Further strengthening its research enterprise, LA BioMed announced today the addition of a new chief scientific officer to its leadership team, Joaquín (Quim) Madrenas, MD, PhD. Dr. Madrenas brings decades of experience as a researcher, physician, educator and administrator to one of the nation’s leading nonprofit independent research institutes.

Higher ICU Usage Led to Increased Invasive Procedures and Costs

New Study of Four Common Conditions Finds ICU Use Didn’t Improve Mortality Rates

LOS ANGELES – With the use of intensive care units (ICUs) on the rise in many hospitals, researchers at LA BioMed and UCLA examined ICU usage and found patients who were admitted to these units underwent more costly and invasive procedures but didn’t have better mortality rates than hospitalized patients with the same medical conditions who weren’t admitted to the ICU.

Two Classes of Medications Associated with Similar Reduction In Cardiovascular Risk in Peritoneal Dialysis Patients

New Study Finds ARB and ACEI Linked to Similar Results

LOS ANGELES – With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.

Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility

Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications

Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility.  In the patent application and a subsequent publication,[1] Ronald S.

Blood Pressure Medications Reduce Stroke and Heart Attack in Peritoneal Dialysis Patients

Jenny I Shen

New Study Finds a 16% Reduction in Cardiovascular Events with the Use of ACEIs and ARBs

Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients with end-stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.

LA BioMed Researchers Editorialize on New Breast Cancer Study in New England Journal of Medicine

They Find Study “Reassuring” and Say it Has Lessons for Cardiologists and Oncologists

In an editorial in the New England Journal of Medicine, LA BioMed Researchers Rowan T. Chlebowski, MD, PhD, and Matthew J. Budoff, MD, said a new study of the long-term use of aromatase inhibitors to prevent the recurrence of certain types of breast cancer is “reassuring,” and they urged oncologists and cardiologists to combine prevention and early detection to prevent disease.

Phoenix Nest and LA BioMed Receive Over $1.7 million to Develop Treatments for Devastating Childhood Disease

Phoenix Nest Inc and LA BioMed Logos

The National Institute of Neurological Disorders and Stroke recently awarded over $1.7 million in grant funding to Phoenix Nest, Inc. to continue its partnership with the Los Angeles Biomedical Institute (LA BioMed) to research the development of therapies for treating different forms of a devastating inherited genetic disorder, Sanfilippo disease, also known as MPS III.